Paper40969762
Breaking barriers: enhancing CAR-armored T cell therapy for solid tumors through microenvironment remodeling.
Andreou T and 4 others. Front Immunol, 2025. Cited by 25 papers, by iCite.
Cite this record
ConductScience Library. Breaking barriers: enhancing CAR-armored T cell therapy for solid tumors through microenvironment remodeling. Papers, record 40969762. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40969762
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Breaking barriers: enhancing CAR-armored T cell therapy for solid tumors through microenvironment remodeling.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Tumor Microenvironment | Major topic |
| Neoplasms | Major topic |
| Immunotherapy, Adoptive | Major topic |
| Receptors, Chimeric Antigen | Major topic |
| T-Lymphocytes | Major topic |
| Humans | |
| Animals |
Source PubMed
References171
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29641319 | Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells. | Hum Gene Ther | 2018 | https://conductscience.org/library/papers/29641319 | PubMed |
| 2 | 25800760 | Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/25800760 | PubMed |
| 3 | 29508855 | Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. | Nat Rev Clin Oncol | 2018 | https://conductscience.org/library/papers/29508855 | PubMed |
| 4 | 29443960 | TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. | Nature | 2018 | https://conductscience.org/library/papers/29443960 | PubMed |
| 5 | 17255361 | Inhibitory effect of tumor cell-derived lactic acid on human T cells. | Blood | 2007 | https://conductscience.org/library/papers/17255361 | PubMed |
| 6 | 35769460 | NK Cells Under Hypoxia: The Two Faces of Vascularization in Tumor and Pregnancy. | Front Immunol | 2022 | https://conductscience.org/library/papers/35769460 | PubMed |
| 7 | 29385370 | Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29385370 | PubMed |
| 8 | 34175021 | Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. | Lancet | 2021 | https://conductscience.org/library/papers/34175021 | PubMed |
| 9 | 35793612 | Scale-out production of extracellular vesicles derived from natural killer cells via mechanical stimulation in a seesaw-motion bioreactor for cancer therapy. | Biofabrication | 2022 | https://conductscience.org/library/papers/35793612 | PubMed |
| 10 | 17606728 | Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. | Clin Cancer Res | 2007 | https://conductscience.org/library/papers/17606728 | PubMed |
| 11 | 12427307 | Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. | Hum Gene Ther | 2002 | https://conductscience.org/library/papers/12427307 | PubMed |
| 12 | 36110930 | Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy. | Front Oncol | 2022 | https://conductscience.org/library/papers/36110930 | PubMed |
| 13 | 39475618 | Metabolic programs drive function of therapeutic NK cells in hypoxic tumor environments. | Sci Adv | 2024 | https://conductscience.org/library/papers/39475618 | PubMed |
| 14 | 39240078 | Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer. | Cancer Res Commun | 2024 | https://conductscience.org/library/papers/39240078 | PubMed |
| 15 | 24876563 | Current concepts in the diagnosis and management of cytokine release syndrome. | Blood | 2014 | https://conductscience.org/library/papers/24876563 | PubMed |
| 16 | 31959281 | T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity. | Elife | 2020 | https://conductscience.org/library/papers/31959281 | PubMed |
| 17 | 32758419 | Chimeric Antigen Receptor Designed to Prevent Ubiquitination and Downregulation Showed Durable Antitumor Efficacy. | Immunity | 2020 | https://conductscience.org/library/papers/32758419 | PubMed |
| 18 | 17108138 | CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. | Cancer Res | 2006 | https://conductscience.org/library/papers/17108138 | PubMed |
| 19 | 21478334 | Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. | Clin Cancer Res | 2011 | https://conductscience.org/library/papers/21478334 | PubMed |
| 20 | 24167277 | Combining two strategies to improve perfusion and drug delivery in solid tumors. | Proc Natl Acad Sci U S A | 2013 | https://conductscience.org/library/papers/24167277 | PubMed |
Cited by21
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42765849 | IL-21 boosts T cell-therapy efficacy for solid tumors by enhancing mitochondrial Ca2+-mediated motility of effector CD8+ T cells. | Cancer Immunol Res | 2026 | https://conductscience.org/library/papers/42765849 | PubMed |
| 42700448 | CRISPR-Engineered CAR-T Cell Therapy for Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma: A Review of Emerging Therapeutic Prospects. | Rev Med Virol | 2026 | https://conductscience.org/library/papers/42700448 | PubMed |
| 42630674 | Cellular Immunotherapy for Cervical Cancer: Next Therapeutics Frontiers. | Oncol Res | 2026 | https://conductscience.org/library/papers/42630674 | PubMed |
| 42509832 | Proteoglycans as Molecular Regulators of Bone Metastasis: Extracellular Matrix Remodeling, Tumor-Bone Crosstalk, Dormancy, and Therapeutic Opportunities. | Biomolecules | 2026 | https://conductscience.org/library/papers/42509832 | PubMed |
| 42454036 | Breaking the resistance barrier: synergistic evolution of CAR-T cells and bispecific antibodies in the era of precision immuno-oncology. | Front Immunol | 2026 | https://conductscience.org/library/papers/42454036 | PubMed |
| 42400102 | Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence. | Biomark Res | 2026 | https://conductscience.org/library/papers/42400102 | PubMed |
| 42316257 | Cellular immunotherapy in melanoma: the next frontier in cancer treatment. | J Exp Clin Cancer Res | 2026 | https://conductscience.org/library/papers/42316257 | PubMed |
| 42183245 | Supercharging the metabolic engine: mitochondrial engineering strategies for CAR-T persistence in solid tumors. | Front Immunol | 2026 | https://conductscience.org/library/papers/42183245 | PubMed |
| 42183218 | Decoding the spatiotemporal dynamics of tumor immune niche remodeling in cancer immunotherapy. | Front Immunol | 2026 | https://conductscience.org/library/papers/42183218 | PubMed |
| 42064077 | PSMA-directed CAR-T cell therapy for metastatic castration-resistant prostate cancer: a next-generation engineering perspective on stem cell-derived immune effectors. | Front Immunol | 2026 | https://conductscience.org/library/papers/42064077 | PubMed |
| 41997128 | Targeting angiogenesis: Lessons from 25 years of normalizing tumor vasculature. | Cell | 2026 | https://conductscience.org/library/papers/41997128 | PubMed |
| 41993194 | CAR-T cells in solid tumors: engineering, biomarkers, translational pathways and the road ahead. | Front Immunol | 2026 | https://conductscience.org/library/papers/41993194 | PubMed |
| 41944897 | CAR-T cell therapy in breast cancer management: expanding horizon and overcoming challenges beyond hematologic cancers. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/41944897 | PubMed |
| 41865195 | Engineering the next generation of cellular therapies for solid tumors: multi-specific armored CARs and TME reprogramming strategies. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/41865195 | PubMed |
| 41859142 | Next-generation immune cell therapies for lung cancer: advances in CAR-T, NK, and TIL strategies. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/41859142 | PubMed |
| 41751878 | In Vivo CAR-T Therapies-A New Era of Programmable Immunity. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41751878 | PubMed |
| 41737839 | Nanomedicine Meets Immunotherapy: Transforming Chimeric Antigen Receptor T Cell Treatment for Solid Tumors. | Small Sci | 2026 | https://conductscience.org/library/papers/41737839 | PubMed |
| 41488642 | CAR-γδ T cells: a new paradigm of programmable innate immune sentinels and their systemic applications in cancer and beyond. | Front Immunol | 2025 | https://conductscience.org/library/papers/41488642 | PubMed |
| 41303538 | Directions of Immunotherapy for Non-Small-Cell Lung Cancer Treatment: Past, Present and Possible Future. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41303538 | PubMed |
| 41303327 | Special Issue "Molecular Advances in Cancer Immunotherapy". | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41303327 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40969762
GET https://conductscience.org/api/papers/v1/40969762/references?page=2